Current Report Filing (8-k)
October 26 2021 - 8:01AM
Edgar (US Regulatory)
0001349929
false
0001349929
2021-10-26
2021-10-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 26, 2021
VYANT
BIO, INC.
(Exact
Name of Company as Specified in its Charter)
Delaware
|
|
001-35817
|
|
04-3462475
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(Address
of Principal Executive Offices) (Zip Code)
Company’s
telephone number, including area code (201) 479-8126
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
VYNT
|
|
The
Nasdaq Capital Market
|
Item
8.01. Other Events.
On
October 26, 2021, Vyant Bio, Inc. (the “Company”) announced the appointment of Robert T. Fremeau Jr., Ph.D. as Chief Scientific
Officer.
Dr.
Fremeau is an experienced R&D leader with over two decades of drug discovery experience in academia and industry advancing next-gen
drug development for severe neurological disorders. He is an accomplished scientist and biotech entrepreneur with an established history
of scientific innovation and program leadership at the intersection of target validation, translation and clinical development. As a
Scientific Director at Amgen Inc., he led and contributed to multiple teams that advanced small molecules into clinical trials against
innovative targets across neurological indications. Throughout his academic career at Duke University and UCSF, Dr. Fremeau made seminal
contributions to the first molecular and functional characterization of the receptors and transporters for the biogenic amine and amino
acid neurotransmitters. Dr. Fremeau holds numerous patents and has authored over 65 peer-reviewed publications in prestigious scientific
journals including: Science, Nature, Neuron, PNAS, Journal of Medicinal Chemistry, and Journal of Neuroscience.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
As
described above, the following exhibits are furnished as part of this report:
Exhibit
99.1 - Press release, dated October 26, 2021.
Exhibit
104 - Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
VYANT
BIO, INC.
|
|
|
|
|
|
|
By:
|
/s/
John A. Roberts
|
|
|
Name:
|
John
A. Roberts
|
|
|
Title:
|
President
and Chief Executive Officer
|
|
|
|
|
Date:
|
October
26, 2021
|
|
|
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Apr 2023 to Apr 2024